SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) July 16, 2004
AEOLUS PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
formerly Incara Pharmaceuticals Corporation
Delaware
(State or other jurisdiction of incorporation)
0-50481 | 56-1953785 | |
(Commission File Number) | (IRS Employer ID Number) |
P.O. Box 14287
79 T. W. Alexander Drive
4401 Research Commons, Suite 200
Research Triangle Park, North Carolina 27709
(Address of principal executive offices) (Zip Code)
Registrants telephone number, including area code (919) 558-8688
Item 5. Other Events and Regulation FD Disclosure
On July 16, 2004, Incara Pharmaceuticals Corporation changed its name to Aeolus Pharmaceuticals, Inc. As a result its stock symbol changed to AOLS.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.
Date: July 20, 2004 |
AEOLUS PHARMACEUTICALS, INC.
/s/ Richard W. Reichow Richard W. Reichow Executive Vice President and Chief Financial Officer |